In the RELATIVITY-047 Phase II/III trial combining Bristol Myers Squibb’s Opdivo with the anti-LAG-3 antibody relatlimab, the drug mashup met the study’s primary goal for progression-free survival compared to use of the blockbuster brand alone in metastatic melanoma patients.
Johnson & Johnson will launch the newly approved drug Ponvory for adults with relapsing multiple sclerosis (MS) in the United States during early April 2021 at a similar price point to rival treatments, the company’s Janssen Pharmaceutical unit said on March 19.
The U.S. Food and Drug Administration approved Genentech’s Actemra (tocilizumab) for slowing the rate of decline in pulmonary function in adults with systemic sclerosis-associated interstitial lung disease (SSc-ILD).
The U.S. Food and Drug Administration approved G1 Therapeutics’ Cosela (trilaciclib) for injection to decrease the damage to the immune system and bone marrow from chemotherapy.
Stephen Byers, Ph.D., associate director and professor of oncology at Georgetown Lombardi, and his team published a paper in the journal Gastroenterology regarding their findings of a novel target for pancreatic cancer therapy.
Previous infection with the coronavirus may offer less protection against the new variant first identified in South Africa, although scientists hope that vaccines will still work.
French pharma giant Sanofi kicked off 2021 with a $1.4 billion cash acquisition of U.K.-based Kymab to bolster the company’s presence in immunology.
Drugmakers agreed to cut prices by around 50% on average for more than 100 medicines in order to have them included in China’s state medical insurance scheme from March, potentially heralding a massive leap in sales.
AstraZeneca and Amgen said their experimental asthma drug tezepelumab failed to meet the main goal of reducing patients’ dependence on steroids, while keeping the respiratory condition in check in a late-stage trial.
Immunai, a company comprehensively mapping the immune system, announced a collaboration with leading life science technology company 10x Genomics.
